218 related articles for article (PubMed ID: 25124163)
1. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
[TBL] [Abstract][Full Text] [Related]
2. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.
Mo S; Ma X; Li Y; Zhang L; Hou T; Han-Zhang H; Qian J; Cai S; Huang D; Peng J
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859741
[TBL] [Abstract][Full Text] [Related]
3. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
4. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
5. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.
McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN
Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250
[TBL] [Abstract][Full Text] [Related]
6. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
7. POLE somatic mutations in advanced colorectal cancer.
Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
[TBL] [Abstract][Full Text] [Related]
8. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
9. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
10. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
[TBL] [Abstract][Full Text] [Related]
12. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
13. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
14. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
15. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
16. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
[TBL] [Abstract][Full Text] [Related]
17. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.
Briggs S; Tomlinson I
J Pathol; 2013 Jun; 230(2):148-53. PubMed ID: 23447401
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
19. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
